Figma Shares Indicated To Open $105/$110
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock has reached a 52-week low, touching down at $105.17. According to InvestingPro data, the company maintains strong fundamentals with a "GREAT" financial health score and impressive revenue growth of ~25% over the last twelve months. This latest price point reflects a significant downturn for the biopharmaceutical company, which specializes in neurologic, psychiatric, and endocrine-related disorders. Over the past year, Neurocrine Biosciences has seen its stock value decrease by 23.65%, indicating a challenging period for the company amidst a volatile market. Despite the price decline, the company maintains robust liquidity with a current ratio of 3.4, and management has been actively buying back shares. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available in the comprehensive Pro Research Report, which provides detailed analysis of NBIX among 1,400+ top US stocks.
In other recent news, Neurocrine Biosciences has announced a new share repurchase program, allowing the company to buy back up to $500 million of its shares. This decision follows the completion of a $300 million accelerated repurchase program. The company aims to balance investment in commercial products, research and development, and returning capital to shareholders. Additionally, Neurocrine Biosciences has commenced a Phase 1 clinical trial for NBI-1140675, a new VMAT2 inhibitor for treating neurological and neuropsychiatric conditions. This trial will assess the safety and tolerability of the compound.
In other developments, RBC Capital Markets has reduced its price target for Neurocrine Biosciences from $148 to $139, citing increased payer restrictions on Ingrezza, which could affect its use and pricing. Despite these challenges, the firm noted that an expanded salesforce might benefit sales this year. Meanwhile, Neurocrine Biosciences presented promising results from a study showing that INGREZZA capsules may lead to remission of tardive dyskinesia symptoms in a significant number of patients. These findings were shared at the 2025 Psychiatry Update Conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.